Michael Heltzen, the Chief Executive Officer of Invizyne Technologies Inc. (NASDAQ:IZTC), a $100 million market cap company, recently acquired additional shares of the company, according to a filing with the Securities and Exchange Commission. According to InvestingPro data, the company currently shows a weak financial health score, making this insider purchase particularly noteworthy. On January 16 and 17, Heltzen purchased a total of 1,888 shares of common stock. The transactions were executed at prices ranging from $10.72 to $10.78 per share, amounting to a total investment of $20,345. The stock, which has shown strong returns over the past three months despite recent short-term weakness, currently trades at $10.56.
The acquisitions increased Heltzen's total holdings to 3,872 shares, highlighting his continued confidence in the company's prospects. The purchases were made directly by Heltzen, indicating a personal investment in Invizyne Technologies, which specializes in biological products. While operating with moderate debt levels, the company's current ratio of 0.25 suggests tight liquidity conditions. Get deeper insights into IZTC's insider trading patterns and 6 additional key metrics with InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.